A global multidimensional analysis of the chimeric antigen receptor T-cell therapy clinical trial landscape and development trends - PubMed
4 hours ago
- #Clinical trials
- #CAR-T therapy
- #Oncology
- CAR-T therapy has advanced significantly in oncology.
- 1,908 CAR-T clinical trials were analyzed using the INFORMA database.
- China (1,006 trials) and the United States (549 trials) accounted for over 80% of all studies.
- Only 4.2% of trials were sex-restricted, and 22% involved children.
- Most studies were early phase, but phase III/IV trials are increasing.
- Research predominantly focused on hematologic malignancies (e.g., non-Hodgkin lymphoma, acute lymphoblastic leukemia, multiple myeloma).
- Progress in solid tumors is slower but advancing.
- CAR-T therapy shows potential in treating autoimmune diseases.
- CD19 and TNF receptor superfamily member 17 are dominant targets, but others (e.g., mesothelin, claudin 18) are being explored.
- Approved CAR-T products (e.g., Axicabtagene ciloleucel, Tisagenlecleucel) have expanded indications and refined strategies.